Cordlife GrouCordlife Group (P8A) Fair Value & Analysis
Healthcare · SG · Market cap 39.7M SGD
Fair value as of: Jul 4, 2026
From 1 valuation models · updated today
Share price +28.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.1210 SGD – 0.2550 SGD · fair‑value band 0.2000 SGD – 0.4100 SGD · the 0.1550 SGD price screens below the 0.2700 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Cordlife GrouCordlife Group (P8A) currently trades at 0.1550 SGD, while our model-based Fair Value estimate is 0.2700 SGD — implying the stock looks roughly 74.2% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Cordlife GrouCordlife Group generated revenue of 38.3M SGD at a net margin of -33.3%. Revenue declined 6.1% year over year. It earns a return on equity of -11.5%. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Cordlife GrouCordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test services. The company also provides corneal lenticule banking, and lifestyle genetic screening services for adults. In addition, it offers life sprouts, medical laboratory, marketing, and property investment services, as well as medical and pharmaceutical research and development and consulting services. Cordlife Group Limited was incorporated in 2001 and is based in Singapore.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cordlife GrouCordlife Group reported revenue of 38.9M SGD in FY2025 versus 56.7M SGD in FY2021, a compound −9.0%/yr. Reported net income was −12.6M SGD in FY2025.
Is P8A fairly valued? → Check now
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $482.04 | $202.02 | -58% |
| Danaher Corporation DHR | $183.63 | $87.65 | -52% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $61.53 | $15.70 | -74% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cordlife GrouCordlife Group (P8A) undervalued?
What is the fair value of P8A?
What is the quality score of P8A?
What is the revenue of Cordlife GrouCordlife Group (P8A)?
What is the net profit margin of P8A?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.